A phase II study of cabozantinib and temozolomide in advanced progressive gastroenteropancreatic or lung neuroendocrine tumors (NETs)

被引：0
|
作者：
Clemente, O. [1 ]
Cives, M. [2 ]
Guerrera, L. P. [1 ]
Tornesello, M. L. [3 ]
Bracigliano, A. [4 ]
Lauricella, E. [5 ]
Ragno, A. [2 ]
Scarpati, G. Della Vittoria [1 ]
Starita, N. [3 ]
Picozzi, F. [1 ]
Barretta, M. L. [6 ]
Badalamenti, G. [2 ,7 ]
Cannella, L. [1 ]
Lastoria, S. [4 ]
Di Mauro, A. [8 ]
Porta, C. G. [2 ]
Tafuto, S. [1 ]
机构：
[1] Ist Nazl Tumori IRCCS Fdn G Pascale, Rare Tumors & Sarcomas Dept, Naples, Italy
[2] Azienda Osped Univ Consorziale Policlin Bari, Med Oncol Unit, Bari, Italy
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Mol Biol & Viral Oncogenesis, Naples, Italy
[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Nucl Med Unit, Naples, Italy
[5] Univ Bari Aldo Moro, Interdisciplinary Dept Med, Bari, Italy
[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Radiol, Naples, Italy
[7] AOU Policlin Paolo Giaccone, Dept Oncol, Palermo, Italy
[8] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Patol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
212P
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [31] Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
    Cwikla, J. B.
    Sankowski, A.
    Seklecka, N.
    Buscombe, J. R.
    Nasierowska-Guttmejer, A.
    Jeziorski, K. G.
    Mikolajczak, R.
    Pawlak, D.
    Stepien, K.
    Walecki, J.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 787 - 794
  • [32] 'Pazonet': Single-arm multicentric phase II trial of pazopanib in patients with progressive gastroenteropancreatic neuroendocrine tumors (GEPNETs)
    Capdevila, J.
    Castellano, D. E.
    Garcia-Carbonero, R.
    Teule, A.
    Duran, I.
    Fuster, J.
    Sevilla, I.
    Escudero, P.
    Sastre, J.
    Grande, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S615 - S616
  • [33] A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.
    Faris, Jason Edward
    Blaszkowsky, Lawrence Scott
    Kwak, Eunice Lee
    Ting, David Tsai
    Zhu, Andrew X.
    Clark, Jeffrey W.
    Allen, Jill N.
    Zheng, Hui
    Duda, Dan G.
    Hong, Theodore S.
    Wo, Jennifer Yon-Li
    Murphy, Janet E.
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    McCleary, Nadine Jackson
    Ng, Kimmie
    Chan, Jennifer A.
    Fuchs, Charles S.
    Ryan, David P.
    Kuike, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Temozolomide plus capecitabine as salvage treatment for patients with advanced neuroendocrine tumors (NETs) in the community setting
    Lopez Lopez, C.
    Jimenez Fonseca, R.
    Crespo Herrero, G.
    Grande Pulido, E.
    Custodio Carretero, A.
    Mangas Izquierdo, M.
    Perez, Q.
    Barrio Alonso, M. J.
    Soria, A.
    Bariuso Feijoo, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S626 - S626
  • [35] A PHASE II PILOT STUDY OF THALIDOMIDE AND TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR PROGRESSIVE BRAIN TUMORS
    Manley, P. E.
    Pietrantonio, J.
    Chi, S. N.
    Lee, M.
    Robison, N.
    Ullrich, N. J.
    Zimmerman, M.
    Chordas, C.
    Goumnerova, L.
    Kieran, M. W.
    NEURO-ONCOLOGY, 2010, 12 (06) : II89 - II90
  • [36] Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
    Chan, Jennifer A.
    Faris, Jason Edward
    Murphy, Janet E.
    Blaszkowsky, Lawrence Scott
    Kwak, Eunice Lee
    McCleary, Nadine Jackson
    Fuchs, Charles S.
    Meyerhardt, Jeffrey A.
    Ng, Kimmie
    Zhu, Andrew X.
    Abrams, Thomas Adam
    Wolpin, Brian M.
    Zhang, Sui
    Reardon, Amanda
    Fitzpatrick, Bridget
    Kulke, Matthew H.
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [37] Gastroenteropancreatic neuroendocrine tumors: A casuistic study
    Costa, F.
    Coelho, A.
    Vizcaino, J. R.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 154 - 154
  • [38] A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET)
    Kalyan, Aparna
    Kircher, Sheetal
    Denlinger, Crystal Shereen
    Berlin, Jordan
    Mulcahy, Mary F.
    Cohen, Steven J.
    Chiorean, E. Gabriela
    Zalupski, Mark
    Benson, Al Bowen
    Nimeiri, Halla Sayed
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [39] Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
    Soares, C.
    Bettencourt, H.
    Preto, J.
    Soares, P.
    Pinto-de-Sousa, J.
    Taveira Gomes, A.
    Costa Maia, J.
    Manuel Lopes, J.
    NEUROENDOCRINOLOGY, 2011, 94 : 11 - 11
  • [40] PROGNOSTIC FACTORS INFLUENCING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETs)
    Arrazubi, Virginia
    Sala, Marian
    Galve, Elena
    Teresa Perez-Hoyos, Maria
    Hinojo, Carmen
    Etxezarraga, Carmen
    Gonzalez, Carmen
    Gomez, Pilar
    Martinez del Prado, Purificacion
    ANNALS OF ONCOLOGY, 2011, 22 : v69 - v69
12345